No evidence for an interaction of the bacterial immunomodulator trehalose dimycolate (TDM) with liver drug-metabolizing system in mice

• Published in: Immunopharmacology and immunotoxicology Vol. 9; no. 4; p. 421
• Main Authors: Zidek, Z, Yanev, S
• Format: Journal Article
• Language: English
• Published: England 1987
• Subjects: Animals; Biotransformation - drug effects; Cord Factors - pharmacology; Glycolipids - pharmacology; Lipid Peroxides - metabolism; Liver - drug effects; Liver - metabolism; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver - metabolism; Mixed Function Oxygenases - metabolism; Pharmaceutical Preparations - metabolism; Proteins - metabolism
• ISSN: 0892-3973
• DOI: 10.3109/08923978709035223

Trehalose dimycolate (TDM), an immunomodulatory glycolipid component of Mycobacteria, was tested from the point of view of possible effects on drug metabolism. TDM was given intraperitoneally as a single 0.1 mg dose to mice. Basic parameters of the liver mixed-function oxidase system were assayed 1 or 7 days later. No significant changes were found in contents of cytochromes P-450 and b5, as well as in specific activities of microsomal enzymes--aniline hydroxylase, ethylmorphine demethylase, and glucuronide transferase. Similarly, liver microsomal protein concentration and activities of serum aspartate and alanine transaminases remained unchanged. The susceptibility of microsomal membranes to lipid peroxidation was significantly decreased 7 days after TDM administration. TDM may thus be presumed not to influence range and magnitude of effects of concurrently administered drugs.